High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
Journal of Antimicrobial Chemotherapy · 06.01.2026 · 81 (1)
DOI: 10.1093/jac/dkaf452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 16.12.2025. Verfasst von Josefine Ahlstrand und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections,…. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Gonorrhea, Anti-Bacterial Agents, Acenaphthenes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: WHO, Örebro County Council Research Committee, Foundation for Medical Research.
Abstract (Originalsprache)
Objectives
The spread of ceftriaxone-resistant Neisseria gonorrhoeae is threatening the last option for gonorrhoea treatment, ceftriaxone. Gepotidacin, the first-in-class triazaacenaphthylene bacterial topoisomerase type IIA inhibitor, recently showed non-inferiority compared to ceftriaxone-azithromycin for treatment of uncomplicated urogenital gonorrhoea in a Phase 3 randomized controlled trial. We evaluated the in vitro susceptibility to gepotidacin in clinical gonococcal isolates (n = 2912), including 125 (4.3%) ceftriaxone-resistant isolates, collected 2021–24 in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) countries in three WHO regions.
Methods
Isolates from Cambodia (n = 474), Indonesia (n = 107), Malawi (n = 111), the Philippines (n = 817), South Africa (n = 578), Thailand (n = 249), Uganda (n = 342) and Vietnam (n = 234) were examined. MICs of gepotidacin were determined using agar dilution. Gepotidacin target genes (gyrA and parC) were examined with Illumina sequencing.
Results
Gepotidacin showed high in vitro activity, with MICs ranging from <0.016 to 4 mg/L. The modal MIC was 0.5 mg/L, MIC₅₀ 0.5 mg/L and MIC₉₀ 1 mg/L. Minor variations in the MIC distributions across countries were observed. ParC D86N, which in suboptimal gepotidacin concentrations predisposes for resistance development, was found in 35.5% of isolates.
Conclusions
We show that the in vitro susceptibility to gepotidacin in N. gonorrhoeae isolates, including 4.3% ceftriaxone-resistant isolates, collected 2021–24 in eight WHO EGASP countries, including five Asian countries, is high. Our findings support gepotidacin’s continued clinical development, registration and introduction as a novel oral treatment for gonorrhoea. However, as with all new novel antimicrobials, cautious and optimal introduction, and surveillance of phenotypic and genomic susceptibility to gepotidacin internationally, pre- and post-licencing, should accompany any clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, National Reference Laboratory for Sexually Transmitted Infections, Ör…
- Global HIV, Hepatitis and STI Programmes, WHO, Geneva, Switzerland.
- National Hospital of Dermatology and Venereology and Hanoi Medical University, Hanoi, Vietnam.
- Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Thailand Ministry of Public Health, Bangkok, Thailand.
- National Center for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Phnom Penh, Cambodia.
- UNC Project Malawi, Lilongwe, Malawi.
ORCID-Profile: Ismael Maatouk, Natnaree Girdthep, Rossaphorn Kittiyaowamarn, Venessa Maseko, Etienne Müller, Hao Trong Nguyen, Magnus Unemo
Förderung
- WHO
- Örebro County Council Research Committee
- Foundation for Medical Research
- Örebro University Hospital
Zitieren
APA
Ahlstrand, J., Maatouk, I., Doanh, L. H., Girdthep, N., Golparian, D., Heng, L. S., Hoffman, I., Jamoralin, M. C., Kakooza, F., Kittiyaowamarn, R., Kyambadde, P., Lan, P. T., Maseko, V., Matoga, M., Müller, E., Nguyen, H. T., Nguyen, T. T. P., Ouk, V., Setiawaty, V., …, & WHO EGASP Gepotidacin Study Group (2026). High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24. Journal of Antimicrobial Chemotherapy, 81(1). https://doi.org/10.1093/jac/dkaf452
Vancouver
Ahlstrand J, Maatouk I, Doanh LH, Girdthep N, Golparian D, Heng LS, et al. High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24. Journal of Antimicrobial Chemotherapy. 2026;81(1). doi:10.1093/jac/dkaf452
BibTeX
@article{Ahlstrand2026,
author = {Ahlstrand, Josefine and Maatouk, Ismael and Doanh, Le Huu and Girdthep, Natnaree and Golparian, Daniel and Heng, Lon Say and Hoffman, Irving and Jamoralin, Manuel C and Kakooza, Francis and Kittiyaowamarn, Rossaphorn and Kyambadde, Peter and Lan, Pham Thi and Maseko, Venessa and Matoga, Mitch and Müller, Etienne and Nguyen, Hao Trong and Nguyen, Thuy Thi Phan and Ouk, Vichea and Setiawaty, Vivi and Sia, Sonia B and Sulaiman, Verawati and Virak, Mot and Thuy Nguyen, Van Thi and Wi, Teodora and Jacobsson, Susanne and Unemo, Magnus and WHO EGASP Gepotidacin Study Group, WHO EGASP Gepotidacin Study Group},
title = {High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {1},
doi = {10.1093/jac/dkaf452}
}
EUVIMED